Seroepidemiological assessment of SARS-CoV-2 vaccine responsiveness and associated factors in the vaccinated community of the Casablanca-Settat Region, Morocco.

Autor: Ezzikouri S; Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, 1 Place Louis Pasteur, 20360, Casablanca, Morocco. sayeh.ezzikouri@pasteur.ma., Tajudeen R; Africa Centres for Disease Control and Prevention, African Union, Addis Ababa, Ethiopia., Majidi H; Ministry of Health and Social Protection, Rabat, Morocco., Redwane S; Direction Régionale de la santé Casablanca-Settat, Observatoire régional de santé, Casablanca, Morocco., Aqillouch S; Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, 1 Place Louis Pasteur, 20360, Casablanca, Morocco., Abdulaziz M; Africa Centres for Disease Control and Prevention, African Union, Addis Ababa, Ethiopia., Aragaw M; Africa Centres for Disease Control and Prevention, African Union, Addis Ababa, Ethiopia., Papa Fallah M; Africa Centres for Disease Control and Prevention, African Union, Addis Ababa, Ethiopia., Sembuche S; Africa Centres for Disease Control and Prevention, African Union, Addis Ababa, Ethiopia., Batcho S; Africa Centres for Disease Control and Prevention, African Union, Addis Ababa, Ethiopia., Kabwe P; Africa Centres for Disease Control and Prevention, African Union, Addis Ababa, Ethiopia., Gonese E; Africa Centres for Disease Control and Prevention, African Union, Addis Ababa, Ethiopia., Laazaazia O; Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, 1 Place Louis Pasteur, 20360, Casablanca, Morocco., Elmessaoudi-Idrissi M; Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, 1 Place Louis Pasteur, 20360, Casablanca, Morocco., Meziane N; Centre Régional de Transfusion Sanguine, Casablanca, Morocco., Ainahi A; Hormonology and Tumor Markers Laboratory, Institut Pasteur du Maroc, Casablanca, Morocco., Sarih M; Service de Parasitologie et des Maladies Vectorielles, Institut Pasteur du Maroc, Casablanca, Morocco., Ogwell Ouma AE; Africa Centres for Disease Control and Prevention, African Union, Addis Ababa, Ethiopia., Maaroufi A; Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, 1 Place Louis Pasteur, 20360, Casablanca, Morocco.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2024 Apr 03; Vol. 14 (1), pp. 7817. Date of Electronic Publication: 2024 Apr 03.
DOI: 10.1038/s41598-024-58498-6
Abstrakt: Assessing the prevalence of SARS-CoV-2 IgG positivity through population-based serological surveys is crucial for monitoring COVID-19 vaccination efforts. In this study, we evaluated SARS-CoV-2 IgG positivity within a provincial cohort to understand the magnitude of the humoral response against the SARS-CoV-2 vaccine and to inform evidence-based public health decisions. A community-based cross-sectional seroprevalence study was conducted, involving 10,669 participants who received various vaccines (two doses for BBIBP-CorV/Sinopharm, Covishield vaccine, and Pfizer/BioNTech, and one dose for Johnson & Johnson's Janssen COVID-19 vaccine). The study spanned 16 provinces in the Casablanca-Settat region from February to June 2022, during which comprehensive demographic and comorbidity data were collected. We screened samples for the presence of IgG antibodies using the SARS-CoV-2 IgG II Quant assay, which quantifies antibodies against the receptor-binding domain (RBD) of the spike (S) protein, measured on the Abbott Architect i2000SR. The overall crude seroprevalence was 96% (95% CI: 95.6-96.3%), and after adjustment for assay performance, it was estimated as 96.2% (95% CI: 95.7-96.6). The adjusted overall seroprevalences according to vaccine brands showed no significant difference (96% for BBIBP-CorV/Sinopharm, 97% for ChAdOx1 nCoV-19/Oxford/AstraZeneca, 98.5% for BNT162b2/Pfizer-BioNTech, and 98% for Janssen) (p = 0.099). Participants of older age, female sex, those with a history of previous COVID-19 infection, and those with certain chronic diseases were more likely to be seropositive among ChAdOx1 nCoV-19/Oxford/AstraZeneca and BBIBP-CorV/Sinopharm vaccinee groups. Median RBD antibody concentrations were 2355 AU/mL, 3714 AU/mL, 5838 AU/mL, and 2495 AU/mL, respectively, after two doses of BBIBP-CorV/Sinopharm, ChAdOx1 nCoV-19/Oxford/AstraZeneca, BNT162b2/Pfizer-BioNTech, and after one dose of Janssen (p < 0.0001). Furthermore, we observed that participants vaccinated with ChAdOx1 nCoV-19/Oxford/AstraZeneca and BBIBP-CorV/Sinopharm with comorbid chronic diseases exhibited a more pronounced response to vaccination compared to those without comorbidities. In contrast, no significant differences were observed among Pfizer-vaccinated participants (p > 0.05). In conclusion, our serosurvey findings indicate that all four investigated vaccines provide a robust humoral immune response in the majority of participants (more than 96% of participants had antibodies against SARS-CoV-2). The BNT162b2 vaccine was found to be effective in eliciting a strong humoral response compared to the other three vaccines. However, challenges still remain in examining the dynamics and durability of immunoprotection in the Moroccan context.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje